.png)
Conference Coverage
Shorts
Podcasts
Continuing Medical Education
All News
Advertisement
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.
Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.
Tori Spelling and Stella McDermott share their journey with eczema, promoting the Free to Be Me campaign and discussing innovative treatments like roflumilast.
Discover the latest advancements in dermatology from the 2025 Elevate-Derm Fall Conference held in Tampa, Florida.
Maui Derm NP+PA Fall 2025 conference showcases cutting-edge insights in dermatology, featuring expert discussions on skin cancer, atopic dermatitis, and rare dermatoses.
Stacey Swinehart, DNP, FNP-BC, DCNP, CNL, shares key takeaways for clinicians from the SDNP's recent webinar on detecting intimate partner violence among patients.
Douglas DiRuggiero receives the prestigious Stead Silver Ford Honorary Award, celebrating his dedication and impact in dermatology and medical education.
Matthew Brunner, MHS, PA-C, discusses upcoming highlights of the 6th annual meeting for dermatology NPs and PAs.
The exclusive event brought together physician assistants and nurse practitioners from across the country to review complex atopic dermatitis, psoriasis, chronic hand eczema, and hidradenitis suppurativa patient cases.
Explore the latest advancements and expert insights from the SDPA Fall 2025 Meeting held in San Antonio, Texas.
Advertisement
What exciting sessions and updates are you looking forward to at the SDPA Fall 2025 Conference in San Antonio? Click here to answer our poll and let us know!
Preview the SDPA Fall 2025 conference in San Antonio for 4 days of networking, education, and expert-led sessions for dermatology PAs.
New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.
Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Pennsylvania Dermatology Physician Assistants (PDPA) Keystone Dermatology Conference in Philadelphia, Pennsylvania.
Selective JAK1 inhibition with upadacitinib may offer a fast-acting, steroid-sparing option for refractory lichen amyloidosis by interrupting IL-31–mediated itch and the itch–scratch cycle.
Advertisement
Advertisement
Trending on Dermatology Times
1
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
2
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
5